Accelerating the New
Glaucoma Paradigm
Accelerating the New
Glaucoma Paradigm
Unlock first-line glaucoma care with DSLT
Consistent, precise treatment at the touch of a button.1
Hydrus® Microstent
The first and only MIGS device to report significant safety and effectiveness outcomes from a pivotal trial at 5 years.2,3
Alcon medical device(s) comply with the current legislation for the medical devices.
Please refer to relevant product’s instructions for use for complete list of indications, contraindications, and warnings.
REFERENCES:
1. Belkin Vision Eagle device user guide, EU. Rev. 7.2; 2024. [REF-24813].
2. Ahmed IIK, et al. Long-term outcomes from the HORIZON randomized trial for Schlemm’s Canal microstent in combination cataract and glaucoma surgery. Ophthalmology. 2022;129(7):742-751.
3. Safety & Effectiveness Study of the Hydrus Microstent for Lowering IOP in Glaucoma Patients. ClinTrials.gov (NCT01539239).
